Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers*

With the increasing demand of providing personalized medicine the need for biobanking of biological material from individual patients has increased. Such samples are essential for molecular research aimed at characterizing diseases at several levels ranging from epidemiology and diagnostic and prognostic classification to prediction of response to therapy. Clinically validated biomarkers may provide information to be used for diagnosis, screening, evaluation of risk/predisposition, assessment of prognosis, monitoring (recurrence of disease), and prediction of response to treatment and as a surrogate response marker. Many types of biological fluids or tissues can be collected and stored in biorepositories. Samples of blood can be further processed into plasma and serum, and tissue pieces can be either frozen or fixed in formalin and then embedded into paraffin. The present review focuses on biological fluids, especially serum and plasma, intended for study of protein biomarkers. In biomarker studies the process from the decision to take a sample from an individual to the moment the sample is safely placed in the biobank consists of several phases including collection of samples, transport of the samples, and handling and storage of samples. Critical points in each step important for high quality biomarker studies are described in this review. Failure to develop and adhere to robust standardized protocols may have significant consequences as the quality of the material stored in the biobank as well as conclusions and clinical recommendations based on analysis of such material may be severely affected.

[1]  N. Brünner,et al.  Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection , 2008, Scandinavian journal of gastroenterology.

[2]  D. Wagner,et al.  Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation , 2005 .

[3]  H. Nielsen,et al.  Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components , 2002, Scandinavian journal of clinical and laboratory investigation.

[4]  T. Mynster Blood transfusion-induced immunomodulation--is storage time important? , 2003, Danish medical bulletin.

[5]  H. Nielsen,et al.  Soluble urokinase plasminogen activator receptor in blood transfusion components , 2004, Transfusion medicine.

[6]  H. Nielsen,et al.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.

[7]  G. Lippi,et al.  Preanalytical variability: the dark side of the moon in laboratory testing , 2006, Clinical chemistry and laboratory medicine.

[8]  H. Nielsen,et al.  Biological Variation in Circulating Levels of Mannan‐Binding Lectin (MBL) and MBL‐Associated Serine Protease‐2 and the Influence of Age, Gender and Physical Exercise , 2007, Scandinavian journal of immunology.

[9]  H. Nielsen,et al.  Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets , 2002, Scandinavian journal of clinical and laboratory investigation.

[10]  H. Nielsen,et al.  Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive protein , 2007, Scandinavian journal of clinical and laboratory investigation.

[11]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[12]  Mario Plebani,et al.  Errors in laboratory medicine. , 2002, Clinical chemistry.

[13]  H. Nielsen,et al.  Evaluation of Sample Handling in Relation to Levels of Tissue Inhibitor of Metalloproteinases-1 Measured in Blood by Immunoassay , 2003, The International journal of biological markers.

[14]  H. Nielsen,et al.  Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates , 2001, American journal of hematology.

[15]  I. Christensen,et al.  Circulating VEGF As a Biological Marker in Patients with Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients , 2007, Disease markers.

[16]  N. Brünner,et al.  Soluble vascular endothelial growth factor in various blood transfusion components , 1999, Transfusion.

[17]  Massimo Gion,et al.  Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. , 2003, International journal of oncology.

[18]  P. Span,et al.  Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. , 2007, The Journal of clinical endocrinology and metabolism.

[19]  D. Hochstrasser,et al.  Impact of preanalytical variables on the analysis of biological fluids in proteomic studies , 2007, Proteomics. Clinical applications.

[20]  H. Nielsen,et al.  Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[21]  H. Nielsen,et al.  Bacterial antigen-induced release of white cell- and platelet-derived bioactive substances in vitro , 2002, International journal of gastrointestinal cancer.

[22]  H. Nielsen,et al.  Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer , 2008, Scandinavian journal of gastroenterology.

[23]  M Plebani,et al.  Mistakes in a stat laboratory: types and frequency. , 1997, Clinical chemistry.

[24]  H. Nielsen,et al.  Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer , 1999, British Journal of Cancer.

[25]  H. Nielsen,et al.  Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. , 2008, The International journal of biological markers.

[26]  Mario Plebani,et al.  Errors in a stat laboratory: types and frequencies 10 years later. , 2007, Clinical chemistry.

[27]  H. Nielsen,et al.  Tissue inhibitor of metalloproteinase‐1 levels in plasma from tumour arteries and veins of patients with rectal cancer , 2007, Scandinavian journal of clinical and laboratory investigation.

[28]  E. Brindle,et al.  C-reactive protein across the menstrual cycle. , 2008, American journal of physical anthropology.